Impact of diabetes against the future risk of developing gout

Annals of the Rheumatic Diseases

Volumn 69, Issue 12, 2010, Pages 2090-2094

  Rodríguez, García ^a   Soriano, Lucia Cea ^a   Choi, Hyon K ^b  

^a Department of Pharmacoepidemiology   (Spain)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; INSULIN; ORAL ANTIDIABETIC AGENT; PROBENECID; URICOSURIC AGENT;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENERAL PRACTITIONER; GOUT; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX; SMOKING; UNITED KINGDOM;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FEMALE; GOUT; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; SEX DISTRIBUTION; YOUNG ADULT;

EID: 78649740305     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.130013     Document Type: Article

References (39)

1. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
2. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
3. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
4. Herman JB, Goldbourt U. Uric acid and diabetes: observations in a population study. Lancet 1982;2:240-3.
5. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels-the third national health and nutrition examination survey. Rheumatology (Oxford) 2008;47:713-17.
6. Cook DG, Shaper AG, Thelle DS, et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J 1986;62:1001-6.
7. Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988;127:321-36.
8. Whitehead TP, Jungner I, Robinson D, et al. Serum urate, serum glucose and diabetes. Ann Clin Biochem 1992;29(Pt 2):159-61.
9. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
10. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7.
11. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175-8.
12. Alonso A, Rodríguez LA, Logroscino G, et al. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696-700.
13. González EL, Johansson S, Wallander MA, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009;63:332-6.
14. Chou P, Lin KC, Lin HY, et al. Gender differences in the relationships of serum uric acid with fasting serum insulin and plasma glucose in patients without diabetes. J Rheumatol 2001;28:571-6.
15. Lee J, Sparrow D, Vokonas PS, et al. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The normative aging study. Am J Epidemiol 1995;142:288-94.
16. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults. Ann Epidemiol 1998;8:250-61.
17. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998;57:509-10.
18. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002;29:1350-5.
19. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120:442-7.
20. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the third national health and nutrition examination survey. Arthritis Rheum 2007;57:109-15.
21. Fortes ZB, Garcia Leme J, Scivoletto R. Vascular reactivity in diabetes mellitus: role of the endothelial cell. Br J Pharmacol 1983;79:771-81.
22. Fortes ZB, Garcia Leme J, Scivoletto R. Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 1984;83:635-43.
23. Llorach MA, Böhm GM, Leme JG. Decreased vascular reactions to permeability factors in experimental diabetes. Br J Exp Pathol 1976;57:747-54.
24. Garcia-Leme J, Böhm GM, Migliorini RH, et al. Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 1974;29:298-306.
25. Garcia Leme J, Hamamura L, Leite MP, et al. Pharmacological analysis of the acute inflammatory process induced in the rat's paw by local injection of carrageenin and by heating. Br J Pharmacol 1973;48:88-96.
26. Cavalher-Machado SC, de Lima WT, Damazo AS, et al. Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin. Eur Respir J 2004;24:552-8.
27. Zanardo RC, Cruz JW, Martinez LL, et al. Probucol restores the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2003;478:211-19.
28. Sannomiya P, Pereira MA, Garcia-Leme J. Inhibition of leukocyte chemotaxis by serum factor in diabetes mellitus: selective depression of cell responses mediated by complement-derived chemoattractants. Agents Actions 1990;30:369-76.
29. Pereira MA, Sannomiya P, Leme JG. Inhibition of leukocyte chemotaxis by factor in alloxan-induced diabetic rat plasma. Diabetes 1987;36:1307-14.
30. Fortes ZB, Farsky SP, Oliveira MA, et al. Direct vital microscopic study of defective leukocyte-endothelial interaction in diabetes mellitus. Diabetes 1991;40:1267-73.
31. de Oliveira Martins J, Meyer-Pflug AR, Alba-Loureiro TC, et al. Modulation of lipopolysaccharide-induced acute lung inflammation: role of insulin. Shock 2006;25:260-6.
32. Boichot E, Sannomiya P, Escofier N, et al. Endotoxin-induced acute lung injury in rats. Role of insulin. Pulm Pharmacol Ther 1999;12:285-90.
33. Alba-Loureiro TC, Martins EF, Landgraf RG, et al. Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. Life Sci 2006;78:578-85.
34. Moriguchi P, Sannomiya P, Lara PF, et al. Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia. Diabetes Metab Res Rev 2005;21:150-7.
35. Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res 2007;40:1037-44.
36. Niskanen L, Laaksonen DE, Lindström J, et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the finnish diabetes prevention study. Diabetes Care 2006;29:709-11.
37. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008;47:1567-70.
38. Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008;31:361-2.
39. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.